Balyasny Asset Management
URGN icon

Balyasny Asset Management’s UroGen Pharma URGN Stock Holding History

Balyasny Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,285
Closed -$235K – 3382
2025
Q1 		$235K Sell
21,285
-3,196
-13% -$34.1K ﹤0.01% 2533
2024
Q4 		$261K Sell
24,481
-4,131
-14% -$49.5K ﹤0.01% 2449
2024
Q3 		$363K Sell
28,612
-145,354
-84% -$2.16M ﹤0.01% 2400
2024
Q2 		$2.92M Buy
173,966
+148,995
+597% +$2.12M 0.01% 1396
2024
Q1 		$375K Buy
+24,971
New +$408K ﹤0.01% 2171
2022
Q4 		– Sell
-11,868
Closed -$99K – 3263
2022
Q3 		$99K Buy
+11,868
New +$98.2K ﹤0.01% 2409

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Balyasny Asset Management's URGN Position: Q2 2025 in Review

Balyasny Asset Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 21,285 shares — an estimated $235K sold.

Balyasny Asset Management first reported a position in URGN in Q3 2022 and held it in 6 quarters. The position peaked at $2.92M in Q2 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Balyasny Asset Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 21,285 UroGen Pharma shares in Q2 2025, an estimated $235K.
  • Balyasny Asset Management first reported a position in UroGen Pharma in Q3 2022 and held it in 6 quarters.
  • Balyasny Asset Management's UroGen Pharma position peaked at $2.92M in Q2 2024.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.